Recent insights into factors affecting remnant lipoprotein uptake

Current Opinion in Lipidology

Volumn 21, Issue 3, 2010, Pages 218-228

  Williams, Kevin Jon ^a   Chen, Keyang ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Diabetes; Heparan sulfate proteoglycans; Insulin resistance; Obesity

Indexed keywords

HEPARAN SULFATE; HEPARAN SULFATE GLUCOSAMINE 6 O ENDOSULFATASE 2; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEOHEPARAN SULFATE; SYNDECAN 1; UNCLASSIFIED DRUG;

CATABOLISM; ENDOCYTOSIS; INSULIN DEPENDENT DIABETES MELLITUS; LIPOPROTEIN METABOLISM; LIVER CLEARANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; PROTEIN TRANSPORT; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; DIABETES MELLITUS; HUMANS; LIPOPROTEINS; LIVER; MOLECULAR SEQUENCE DATA; POSTPRANDIAL PERIOD; RECEPTORS, LDL;

EID: 77952335030     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328338cabc     Document Type: Review

References (139)

1. Moreton JR. Atherosclerosis and alimentary hyperlipemia. Science 1947; 106:190-191.
2. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60:473-485.
3. Karpe F, Boquist S, Tang R, et al. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001; 42:17-21.
4. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298:299-308.
5. Björkegren J, Boquist S, Samnegard A, et al. Accumulation of apolipoprotein C-I-rich and cholesterol-rich VLDL remnants during exaggerated postprandial triglyceridemia in normolipidemic patients with coronary artery disease. Circulation 2000; 101:227-230.
6. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)-and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002; 13:461-470.
7. Williams KJ, Tabas I. Lipoprotein retention-and clues for atheroma regression. Arterioscler Thromb Vasc Biol 2005; 25:1536-1540.
8. Flood C, Gustafsson M, Richardson PE, et al. Identification of the proteo-glycan binding site in apolipoprotein B48. J Biol Chem 2002; 277:32228-32233.
9. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 1995; 15:551-561.
10. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112:3547-3553.
11. Dane-Stewart CA, Watts GF, Barrett PH, et al. Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without type 2 diabetes mellitus. Clin Endocrinol (Oxf) 2003; 58:415-420.
12. Hogue JC, Lamarche B, Tremblay AJ, et al. Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes. J Lipid Res 2007; 48:1336-1342.
13. Williams KJ. Molecular processes that handle-and mishandle-dietary lipids. J Clin Invest 2008; 118:3247-3259.
14. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298:309-316.
15. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300:2142-2152.
16. Karpe F, Hamsten A. Postprandial lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol 1995; 6:1 23-129.
17. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999; 19:2474-2486.
18. Adiels M, Olofsson S-O, Taskinen M-R, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008; 28:1225-1236.
19. Celi FS. Brown adipose tissue: when it pays to be inefficient. N Engl J Med 2009; 360:1553-1556.
20. Parhofer KG, Barrett PH, Schwandt P. Atorvastatin improves postprandial lipoprotein metabolism in normolipidemlic subjects. J Clin Endocrinol Metab 2000; 85:4224-4230.
21. Parhofer K. Postprandial lipid metabolism: is it relevant? XVI Lipid Meeting; Leipzig; 2009. http://www.lipidmeeting.de/download/LM09-Tagungsband- final.pdf.
22. Kane JP, Hardman DA, Paulus HE. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci USA 1980; 77:2465-2469.
23. Sparks CE, Marsh JB. Metabolic heterogeneity of apolipoprotein B in the rat. J Lipid Res 1981; 22:519-527.
24. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232:34-47.
25. Cohn JS, McNamara JR, Cohn SD, et al. Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed afat-rich meal. J Lipid Res 1988; 29:925-936.
26. Schneeman BO, Kotite L, Todd KM, Havel RJ. Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apo-lipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans. Proc Natl Acad Sci USA 1993; 90:2069-2073.
27. Cohn JS, Johnson EJ, Millar JS, et al. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters. J Lipid Res 1993; 34:2033-2040.
28. Karpe F, Bell M, Bjorkegren J, Hamsten A. Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100. Arterioscler Thromb Vasc Biol 1995; 15:199-207.
29. Veniant MM, Pierotti V, Newland D, et al. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J Clin Invest 1997; 100:180-188.
30. Weinstein MM, Yin L, Tu Y, et al. Chylomicronemia elicits atherosclerosis in mice: brief report. Arterioscler Thromb Vasc Biol 2010; 30:20-23.
31. Felts JM, ItakuraH, Crane RT.The mechanisms of assimilation of constituents of chylomicrons, very low density lipoproteins and remnants: a new theory. Biochem Biophys Res Commun 1975; 66:1467-1475.
32. Williams KJ, Fless GM, Petrie KA, et al. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein (a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans. J Biol Chem 1992; 267: 13284-13292.
33. Fuki IV, Kuhn KM, Lomazov IR, et al. The syndecan family of proteoglycans: novel receptors mediating internalization of atherogenic lipoproteins in vitro. J Clin Invest 1997; 100:1611-1622.
34. Zheng C, Murdoch SJ, Brunzell JD, Sacks FM. Lipoprotein lipase bound to apolipoprotein B lipoproteins accelerates clearance of postprandial lipoproteins in humans. Arterioscler Thromb Vasc Biol 2006; 26:891-896.
35. Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipo-proteinemia. J Biol Chem 1994; 269:13421-13428.
36. Mann WA, Meyer N, Weber W, et al. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. J Lipid Res 1995; 36:517-525.
37. Mortimer BC, Beveridge DJ, Martins IJ, Redgrave TG. Intracellular localization and metabolism of chylomicron remnants in the livers of low density lipoprotein receptor-deficient mice and apoE-deficient mice. Evidence for slow metabolism via an alternative apoE-dependent pathway. J Biol Chem 1995; 270:28767-28776.
38. Bradley WA, Hwang S-LC, Karlin JB, et al. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J Biol Chem 1984; 259:14728-14735.
39. Zambon A, Deeb SS, Bensadoun A, et al. In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. J Lipid Res 2000; 41:2094-2099.
40. Dichek HL, Qian K, Agrawal N. The bridging function of hepatic lipase clears plasma cholesterol in LDL receptor-deficient 'apoB-48-only' and 'apoB-100-only' mice. J Lipid Res 2004; 45:551-560.
41. López-Miranda J, Pérez-Martinez P, Maŕ?n C, et al. Postprandial lipoprotein metabolism, genes and risk of cardiovascular disease. Curr Opin Lipidol 2006; 17:132-138.
42. Nilsson SK, Lookene A, Beckstead JA, et al. Apolipoprotein A-V interaction with members of the low density lipoprotein receptor gene family. Biochemistry 2007; 46:3896-3904.
43. Forte TM, Shu X, Ryan RO. The ins (cell) and outs (plasma) of apolipoprotein A-V. J Lipid Res 2009; 50 (Suppl):S150-S155.
44. Merkel M. New aspects of ApoA5. XVI Lipid Meeting; Leipzig; 2009. http://www.lipidmeeting.de/download/LM09-Tagungsband-final.pdf.
45. Gangabadage CS, Zdunek J, Tessari M, et al. Structure and dynamics of human apolipoprotein CIII. J Biol Chem 2008; 283:17416-17427.
46. Zheng C, Khoo C, Ikewaki K, Sacks FM. Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J Lipid Res 2007; 48:1190-1203.
47. Schissel SL, Jiang X-C, Tweedie-Hardman J, et al. Secretory sphingomye-linase, a product of the acid sphingomyelinase gene, can hydrolyze athero-genic lipoproteins at neutral pH: implications for atherosclerotic lesion development. J Biol Chem 1998; 273:2738-2746.
48. Hiukka A, Stahlman M, Pettersson C, et al. ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan. Diabetes 2009; 58:2018-2026.
49. KitaT, Goldstein JL, Brown MS, et al. Hepatic uptake of chylomicron remnants in WHHL rabbits: a mechanism genetically distinct from the low density lipoprotein receptor. Proc Natl Acad Sci USA 1982; 79:3623-3627.
50. Hoeg JM, Demosky SJ Jr, Gregg RE, et al. Distinct hepatic receptors for low density lipoprotein and apolipoprotein E in humans. Science 1985; 227:759-761.
51. Rubinsztein DC, Cohen JC, Berger GM, et al. Chylomicron remnant clearance from the plasma is normal in familial hypercholesterolemic homozygotes with defined receptor defects. J Clin Invest 1990; 86:1306-1312.
52. Herz J, Qiu SQ, Oesterle A, et al. Initial hepatic removal of chylomicron remnants is unaffected but endocytosis is delayed in mice lacking the low density lipoprotein receptor. Proc Natl Acad Sci USA 1995; 92:4611-4615.
53. Williams KJ, Fuki IV. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism. Curr Opin Lipidol 1997; 8:253-262.
54. Williams KJ, Fless GM, Petrie K, et al. Lipoprotein lipase enhances cellular catabolism of lipoprotein(a). Circulation 1991; 84 (Suppl II):566.
55. EbaraT, Conde K, Kako Y, et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 2000; 105:1807-1818.
56. MacArthur JM, Bishop JR, Stanford KI, et al. Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest 2007; 117:153-164.
57. Chajek-Shaul T. Manipulation of heparanase expression affects postprandial lipemia and atherosclerotic plaque development in mice. XVI Lipid Meeting; Leipzig; 2009. http://www.lipidmeeting.de/download/LM09-Tagungsband- final.pdf.
58. Williams KJ. Interactions of lipoproteins with proteoglycans. Methods Mol Biol 2001; 171:457-477.
59. Lyon M, Deakin JA, Gallagher JT. Liver heparan sulfate structure. A novel molecular design. J Biol Chem 1994; 269:11208-11215.
60. Bernfield M, Kokenyesi R, Kato M, et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol 1992; 8:365-393.
61. David G. Integral membrane heparan sulfate proteoglycans. FASEB J 1993; 7:1023-1030.
62. Zimmermann P, David G. The syndecans, tuners of transmembrane signaling. FASEB J 1999; 13 (Suppl):S91-S100.
63. Hayashi K, Hayashi M, Jalkanen M, et al. Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissue. A light and electron microscopic study. J Histochem Cytochem 1987; 35:1079-1088.
64. Roskams T, Moshage H, De Vos R, et al. Heparan sulfate proteoglycan expression in normal human liver. Hepatology 1995; 21:950-958.
65. Stanford KI, Bishop JR, Foley EM, et al. Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipopro teins in mice. J Clin Invest 2009; 119:3236-3245.
66. Fuki IV, Meyer ME, Williams KJ. Transmembrane and cytoplasmic domains of syndecan mediate a multistep endocytic pathway involving detergent-insoluble membrane rafts. Biochem J 2000; 351:607-612.
67. Li X, Herz J, Monard D. Activation of ERK signaling upon alternative protease nexin-1 internalization mediated by syndecan-1. J Cell Biochem 2006; 99:936-951.
68. Chen K, Liu M-L, Williams KJ. Molecular determinants of endocytosis and tyrosine phosphorylation within the cytoplasmic tail of human syndecan-1, a receptor for remnant lipoproteins. Circulation 2008; 118:S453.
69. Spring J, Paine-SaundersSE, Hynes RO, Bernfield M. Drosophila syndecan: conservation of a cell-surface heparan sulfate proteoglycan. Proc Natl Acad Sci USA 1994; 91:3334-3338.
70. 13C-n.m.r.-spectral evidence. Carbohydr Res 1988; 184:292-300.
71. Chan DC, Watts GF, Barrett PH, et al. Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. J Lipid Res 2002; 43:706-712.
72. 48 metabolism and low-density lipoprotein receptor activity in normo-lipidemic patients with coronary artery disease. Metabolism 2003; 52:1279-1286.
73. Boquist S, Karpe F, Danell-Toverud K, Hamsten A. Effects of atorvastatin on postprandial plasma lipoproteins in postinfarction patients with combined hyperlipidaemia. Atherosclerosis 2002; 162:163-170.
74. Schaefer EJ, McNamara JR, Tayler T, et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 2004; 93:31-39.
75. Karalis DG, Ishisaka DY, Luo D, et al. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. Am J Cardiol 2007; 100:445-449.
76. Windler E, Greeve J, Robenek H, et al. Differences in the mechanisms of uptake and endocytosis of small and large chylomicron remnants by rat liver. Hepatology 1996; 24:344-351.
77. Rensen PC, Herijgers N, Netscher MH, et al. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res 1997; 38:1070-1084.
78. Ishibashi S, Perrey S, Chen Z, et al. Role of the low density lipoprotein (LDL) receptor pathway in the metabolism of chylomicron remnants. A quantitative study in knockout mice lacking the LDL receptor, apolipoprotein E, or both. J Biol Chem 1996; 271:22422-22427.
79. Goldstein JL, Brown MS. Atherosclerosis: the low-density lipoprotein receptor hypothesis. Metabolism 1977; 26:1257-1275.
80. Kesaniemi YA, Witztum JL, Steinbrecher UP. Receptor-mediated catabolism of low density lipoprotein in man.Quantitation using glucosylated low density lipoprotein. J Clin Invest 1983; 71:950-959.
81. Goldberg IJ, Hu Y, Noh HL, et al. Decreased lipoprotein clearance is responsible for increased cholesterol in LDL receptor knockout mice with streptozotocin-induced diabetes. Diabetes 2008; 57:1674-1682.
82. Fu T, Kozarsky KF, Borensztajn J. Overexpression of SR-BI by adenoviral vector reverses the fibrate-induced hypercholesterolemia of apolipoprotein E-deficient mice. J Biol Chem 2003; 278:52559-52563.
83. Out R, Kruijt JK, Rensen PC, et al. Scavenger receptor BI plays a role in facilitating chylomicron metabolism. J Biol Chem 2004; 279:18401-18406.
84. Out R, Hoekstra M, de Jager SC, et al. Adenovirus-mediated hepatic over-expression of scavenger receptor class B type I accelerates chylomicron metabolism in C57BL/6J mice. J Lipid Res 2005; 46:1172-1181.
85. Van Eck M, Hoekstra M, Out R, et al. Scavenger receptor BI facilitates the metabolism of very-low-density lipoproteins in vivo. J Lipid Res 2008; 49:136-146.
86. Kowal RC, Herz J, Goldstein JL, et al. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci USA 1989; 86:5810-5814.
87. Hussain MM, Ji ZS, Mahley RW, et al. Clearance of chylomicron remnants by the low density lipoprotein receptor-related protein/a2-macroglobulin receptor. J Biol Chem 1991; 266:13936-13940.
88. Mokuno H, Herz J, Havel RJ, et al. Effect of the 39-kDa receptor-associated protein on the hepatic uptake and endocytosis of chylomicron remnants and low density lipoproteins in the rat. J Biol Chem 1994; 269:13238-13243.
89. Rohlmann A, Gotthardt M, Hammer RE, Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms role of LRP in clearance of chylomicron remnants. J Clin Invest 1998; 101:689-695.
90. Laatsch A, Merkel M, Talmud PJ, et al. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipo protein clearance. Atherosclerosis 2009; 204:105-111.
91. Webb NR, de Beer MC, de Beer FC, van der Westhuyzen DR. ApoB-containing lipoproteins in apoE-deficient mice are not metabolized by the class B scavenger receptor BI. J Lipid Res 2004; 45:272-280.
92. Acton S, Rigotti A, Landschulz KT, et al. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science 1996; 271:518-520.
93. Georgopoulos A, Phair RD. Abnormal clearance of postprandial Sf 100-400 plasma lipoproteins in insulin-dependent diabetes mellitus. J Lipid Res 1991; 32:1133-1141.
94. Chan DC, Barrett PH, Watts GF. Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 2006; 17:28-36.
95. Niesen M, Bedi M, Lopez D. Diabetes alters LDL receptor and PCSK9 expression in rat liver. Arch Biochem Biophys 2008; 470:111-115.
96. Han S, Liang CP, Westerterp M, et al. Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice. J Clin Invest 2009; 119:1029-1041.
97. Milliat F, Gripois D, Blouquit ME, et al. Short and long-term effects of streptozotocin on dietary cholesterol absorption, plasma lipoproteins and liver lipoprotein receptors in RICO rats. Exp Clin Endocrinol Diabetes 2000; 108:436-446.
98. Shetty S, Eckhardt ER, Post SR, van der Westhuyzen DR. Phosphatidyli-nositol-3-kinase regulates scavenger receptor class B type I subcellular localization and selective lipid uptake in hepatocytes. Arterioscler Thromb Vasc Biol 2006; 26:2125-2131.
99. Murao K, Yu X, Imachi H, et al. Hyperglycemia suppresses hepatic scavenger receptor class B type I expression. Am J Physiol 2007; 294:E78-87.
100. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem 2002; 71:435-471.
101. Grobe K, Esko JD. Regulated translation of heparan sulfate N-acetylgluco-samine N-deacetylase/N-sulfotransferase isozymes by structured 5'-untrans-lated regions and internal ribosome entry sites. J Biol Chem 2002; 277:30699-30706.
102. Williams KJ, Liu M-L, Zhu Y, et al. Loss of heparan N-sulfotransferase in diabetic liver: role of angiotensin II. Diabetes 2005; 54:1116-1122.
103. Ledin J, Ringvall M,Thuveson M, et al. Enzymatically active N-deacetylase/N-sulfotransferase-2 is present in liver but does not contribute to heparan sulfate N-sulfation. J Biol Chem 2006; 281:35727-35734.
104. Kjellén L, Bielefeld D, Hook M. Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 1983; 32:337-342.
105. Kjellén L. Glucosaminyl N-deacetylase/N-sulphotransferases in heparan sulphate biosynthesis and biology. Biochem Soc Trans 2003; 31:340-342.
106. Mulloy B, Forster MJ. Conformation and dynamics of heparin and heparan sulfate. Glycobiology 2000; 10:1147-1156.
107. Scott JE. Elasticity in extracellular matrix'shape modules' of tendon, cartilage, etc. A sliding proteoglycan-filament model. J Physiol 2003; 553:335-343.
108. Duran-Sandoval D, Mautino G, Martin G, et al. Glucose regulates the expression of thefarnesoid X receptor in liver. Diabetes 2004; 53:890-898.
109. Anisfeld AM, Kast-Woelbern HR, Meyer ME, et al. Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor. J Biol Chem 2003; 278:20420-20428.
110. Olsson U, Egnell AC, Lee MR, et al. Changes in matrix proteoglycans induced by insulin and fatty acids in hepatic cells may contribute to dysli-pidemia of insulin resistance. Diabetes 2001; 50:2126-2132.
111. Rohrbach DH, Hassell JR, Kleinman HK, Martin GR. Alterations in the basement membrane (heparan sulfate) proteoglycan in diabetic mice. Diabetes 1982; 31:185-188.
112. Comelli EM, Head SR, Gilmartin T, et al. A focused microarray approach to functional glycomics: transcriptional regulation of the glycome. Glycobiology 2006; 16:117-131.
113. Chen K, Liu M-L, Schaffer L, et al. Type 2 diabetes strongly induces hepatic overexpression of SULF2, a novel factor that suppresses uptake of remnant lipoproteins. Atheroscler Suppl 2009; 10:e280.
114. Uchimura K, Morimoto-Tomita M, Rosen SD. Measuring the activities of the Sulfs: two novel heparin/heparan sulfate endosulfatases. Methods Enzymol 2006; 416:243-253.
115. Lai JP, Sandhu DS, YuC, et al. Sulfatase 2 up-regulatesglypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 2008; 47:1211-1222.
116. Parthasarathy N, Goldberg IJ, Sivaram P, Wagner WD. Isolation of heparin-derived oligosaccharides containing 2-O-sulfated hexuronic acids, by lipoprotein lipase affinity chromatography. J Biochem Biophys Methods 1996; 32:27-32.
117. Stanford KI, Wang L, Castagnola J, et al. Heparan sulfate 2-O-sulfotransfer-ase is required for triglyceride-rich lipoprotein clearance. J Biol Chem 2010; 285:286-294.
118. Lamanna WC, Frese MA, Balleininger M, Dierks T. Sulf loss influences N-, 2O-, and 6O-sulfation of multiple heparan sulfate proteoglycans and modulates FGF signaling. J Biol Chem 2008; 283:27724-27735.
119. Chen K, Liu M-L, Li M, et al. Metabolic factors in type 2 diabetes augment hepatocyte expression of SULF2, a novel suppressor of remnant lipoprotein uptake. Circulation 2009; 120:S1175.
120. Martins IJ, Tran JM, Redgrave TG. Food restriction normalizes chylomicron remnant metabolism in murine models of obesity as assessed by a novel stable isotope breath test. J Nutr 2002; 132:176-181.
121. Ybarra J, James RW, Makoundou V, et al. Effects of short-term modest weight loss on fasting and postprandial lipoprotein sub-fractions in type 2 diabetes mellitus patients. Diabetes Metab 2001; 27:701-708.
122. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5:150-159.
123. Liu M-L, Davidson WR, Meyer ME, et al. An unexpected consensus motif shared by the LDL receptor and syndecan transmembrane domains directs movement into rafts upon clustering. Arterioscler Thromb Vasc Biol 2004; 24:E-53.
124. Babitt J, Trigatti B, Rigotti A, et al. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272:13242-13249.
125. Burgos PV, Klattenhoff C, de la Fuente E, et al. Cholesterol depletion induces PKA-mediated basolateral-to-apical transcytosis of the scavenger receptor class B type I in MDCK cells. Proc Natl Acad Sci USA 2004; 101:3845-3850.
126. Beaslas O, Cueille C, Delers F, et al. Sensing of dietary lipids by enterocytes: a new role for SR-BI/CLA-1. PLoS One 2009; 4:e4278.
127. Tkachenko E, Lutgens E, Stan RV, Simons M. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci 2004; 117:3189-3199.
128. Wilsie LC, Gonzales AM, Orlando RA. Syndecan-1 mediates internalization of apoE-VLDL through a low density lipoprotein receptor-related protein (LRP)-independent, nonclathrin-mediated pathway. Lipids Health Dis 2006; 5:23.
129. Hansen GH, Niels-Christiansen LL, Immerdal L, Danielsen EM. Scavenger receptor class B type I (SR-BI) in pig enterocytes: trafficking from the brush border to lipid droplets during fat absorption. Gut 2003; 52:1424-1431.
130. Tabas I, Myers JN, Innerarity TL, et al. The influence of particle size and multiple apoprotein E-receptor interactions on the endocytic targeting of b-VLDL in mouse peritoneal macrophages. J Cell Biol 1991; 115:1547-1560.
131. Rodrigueza WV, Mazany KD, Essenburg AD, et al. Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:2132-2139.
132. Kotzka J, Lehr S, Roth G, et al. Insulin-activated Erk-mitogen-activated protein kinases phosphorylate sterol regulatory element-binding protein-2 at serine residues 432 and 455 in vivo. J Biol Chem 2004; 279:22404-22411.
133. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol 2005; 25:2170-2176.
134. Arito M, Horiba T, Hachimura S, et al. Growth factor-induced phosphorylation of sterol regulatory element-binding proteins inhibits sumoylation, thereby stimulating the expression of their target genes, low density lipoprotein uptake, and lipid synthesis. J Biol Chem 2008; 283:15224-15231.
135. Roerdink F, Dijkstra J, Hartman G, et al. The involvement of parenchymal, Kupffer and endothelial liver cells in the hepatic uptake of intravenously injected liposomes. Effects of lanthanum and gadolinium salts. Biochim Biophys Acta 1981; 677:79-89.
136. Pieters MN, Esbach S, Schouten D, et al. Cholesteryl esters from oxidized low-density lipoproteins are in vivo rapidly hydrolyzed in rat Kupffer cells and transported to liver parenchymal cells and bile. Hepatology 1994; 19:1459-1467.
137. Norum KR, BlomhoffR.McCollum Award Lecture, 1992: vitaminAabsorption, transport, cellular uptake, and storage. Am J Clin Nutr 1992; 56:735-744.
138. Heeren J. Novel insights in postprandial lipoprotein pathways. XVI Lipid Meeting; Leipzig; 2009. http://www.lipidmeeting.de/download/LM09-Tagungsband- final.pdf.
139. Lusis AJ, Pajukanta P. A treasure trove for lipoprotein biology. Nat Genet 2008; 40:129-130.